ROXANE LABORATORIES, INC.ANNOUNCES THE LAUNCH OF NEVIRAPINE TABLETS AND ORAL SUSPENSION

COLUMBUS, OH – May 22, 2012 – Roxane Laboratories, Inc. announced today the launch of Nevirapine Tablets, 200mg and Nevirapine Oral Suspension, 50mg/5mL. The tablets are available in 200mg bottles of 60 while the 50mg/5mL Oral Suspension is available in a 240mL bottle. Both the tablets and oral suspension are available for immediate shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories’ Nevirapine Tablets and Nevirapine Oral Suspension are the Authorized Generics of VIRAMUNE® (nevirapine) tablets and oral suspension.

Full prescribing information for Nevirapine Tablets and Nevirapine Oral Suspension is available on the Roxane Laboratories website at www.RLI-TouchPoint.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.
Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 80 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlledrelease tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

For more information, please visit http://www.Roxane.com.

AboutBoehringer Ingelheim
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since
it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

For more information, please visit http://us.boehringer-ingelheim.com.

 

VIRAMUNE® is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc.